Home - HARMONY Alliance

Get Involved

Pam Bacon

HARMONY Co-Lead, Celgene

"HARMONY will to allow us to understand the outcomes that matter to patients and through the big data platform, identify targets, risk factors or treatments which will accelerate access of

John E. Butler

Ransohoff, VP, Global External Innovation, Bayer

"The HARMONY consortium is committed to enabling the use of high-quality clinical and genomic data for the benefit of patients with Hematological Malignancies. Our consortium provides a solid and ...

Ellen de Waal

HARMONY Communication Manager, European Hematology Association

"We will make a difference by communicating about real developments and achievements which are realized by the teams of the HARMONY Work Packages, HM Disease Groups and Research Projects. Through ...

Anthony Moorman

Newcastle University, HARMONY Key Opinion Leaders for Childhood Leukemia

"Sharing data is crucial to further research in Hematological Malignancies because many of these cancers are heterogeneous in terms of their genetic profile. Many genetic profiles are rare;

Renate Schulze-Rath

Director, Oncology1/WHC, Bayer

"Looking forward to working together with so many public and private partners on defining outcomes sets for HMs which include both clinical outcome measures and patient factors for patients and caregivers.The ...

Lars Bullinger

Professor in Personalized Medicine, Charité

"Hematological malignancies (HMs) are a role model for the treatment of many cancers. Being characterized by a tremendous heterogeneity, HMs are hard to come by with “one size fits all” ...

Michel van Speybroeck

Director Data Sciences, JPNV-JANSSEN

"Public and private partners are bringing together their best people, data, and knowledge to solve key questions on hematological cancers. These challenges can only be met by applying the most advanced ...

Rubén Villoria Medina

Project Coordinator, GMV Soluciones Globales Internet (GMV)

"The Big Data platform, to be developed in WP3, will support data homogenization on a common data model to create relationships and allow advance analysis and studies between treatments, health

Gastone Castellani

Professor Department of Physics and Astronomy Academic discipline. Alma Mater Studiorum - Università di Bologna

"WP5 aims to develop methodologies for statistical analysis and modelling of both molecular and clinical data coming from patients with hematological malignancies, identifying possible specific disease ...

Simona Scartoni

Head of Biostatistics and Data Management, Menarini Ricerche

"The challenge of WP5 is to provide methodologies to analyze data, integrating clinical and non-clinical information, to build a predictive tool in a personalized medicine framework."

Alun Passey

Real World Evidence Research Associate, JPNV-JANSSEN

"The over-arching goal of the HARMONY Alliance is to integrate patient data from molecular omics, treatment pathways and social and economic impacts to generate novel algorithmic approaches which ...

Jan Geissler

Founder and CEO, LeukaNET

"HARMONY helps improve the prognosis and outcome of patients with hematological cancers, driven by knowledge derived from the combination and analysis of complex data. This will only make

European Public-Private Partnership for Big Data in Hematology.

Big Data Platform

Data barometer

Become involved

Campaign

News

Meet us